

We couldn't have done it without you. We appreciate your ongoing support



P2 / NOW REPORTABLE &
A SNAPSHOT OF HPV-IMPACT
Cervical pre-cancer now
reportable in Alameda County




VACCINE IN THE NEWS

Decrease in genital warts
and vaccine-type prevalence



P4 / WHO SHOULD GET
THE VACCINE & HOW YOU
CAN HELP
Improving for the future

HPV-IMPACT Upacte ISSUE 5 WINTER EDITION 2014



Left to right: Erin Whitney—Surveillance Coordinator, Dr. Ina Park—Principal Investigator, Dr. Heidi Bauer—Co-Investigator, Ashley Williamson—Operations Officer, Nancy Pham—Research Assistant

HPV-Impact is a collaboration between the California Department of Public Health (CDPH), Sexually Transmitted Diseases (STD) Control Branch, the California Emerging Infections Program (CEIP), the Alameda County Public Health Department (ACPHD) and the Centers for Disease Control and Prevention (CDC).

The goal of HPV-Impact is to establish ongoing population-based surveillance of

high-grade cervical pre-cancer, specifically cervical intraepithelial neoplasia (CIN) grades 2 and 3 and adenocarcinoma in situ (AIS) and to monitor the impact of the HPV vaccines over time. The catchment area for the surveillance is Alameda County. Currently, 18 laboratories are providing surveillance case data

The support of histopathology laboratories and medical providers serving

Alameda County residents is vital for the success of this project. Full reporting provides a complete picture of the burden of cervical pre-cancer; HPV typing of cervical tissue tells us about circulating strains of the virus; and recording vaccine history tracks impact on disease.







HPV-IMPACT ANNOUNCEMENT

Cervical pre-cancer now reportable in Alameda County

Beginning September 2013, CIN2/3/AIS became a reportable condition in Alameda County. With the help of labs and providers, we will continue to capture the data necessary to understand the impact of the HPV vaccines.

ROLE OF LABORATORIES

- ♦ Coordinate reporting method with **HPV-Impact Surveillance Unit:** electronic or paper-based
- Report any cases of high-grade CIN or AIS among Alameda County residents over 18 years of age
- Provide fixed cervical tissue specimens upon request for HPV typing by CDC

ROLE OF PROVIDERS

- Provide missing demographic data, HPV vaccination history, and cervical cancer screening history
- Record patient HPV vaccine history
- Encourage HPV vaccination and completion of the 3-dose series



Q. Is this reportable elsewhere?

A. Yes: Los Angeles County, Connecticut, Oregon, Michigan, Kentucky, and Tennessee

Q. Can someone help us with a reporting mechanism?

A. Yes. Resources may be available to assist with reporting. Please call (510) 620-2379 or visit http://ceip.us/projects/hpv-impact/

Q. Will providers receive HPV typing results for clinical care?

A. No. All typing data is provided in aggregate. The long delay in obtaining and receiving typing data makes it no longer clinically relevant.

What to Report

CIN 2, 2/3, 3

AIS

HSIL

Moderate or Severe Dysplasia ICD-9 Codes 622.12, 233.1



THE CALIFORNIA HPV-IMPACT PROJECT




GOAL

Conduct population-based surveillance of high grade cervical precancer to monitor the impact of the **HPV** vaccines

Surveillance began Jan 1 2008 and is expected to continue over 18 years of until at least 2018

Female Alameda County residents



Cases identified by any local or national pathology lab processing cervical tissue specimens

Minors may consent for STD prevention services

On January 1, 2012, California Law AB499 permits adolescents 12-17 years old to consent to confidential services for the prevention of sexually transmitted diseases without parental consent.

Prevention services could include:

- Human papillomavirus vaccination
- Hepatitis B vaccination
- HIV pre- and post-exposure medication

>> Get the FAQs: http://www.cdph.ca.gov/programs/std/ Documents/AB-499-Fact-Sheet.pdf



image via flickr, Queens University

HPV VACCINE in the news

HPV vaccines working but US vaccination rates stall in 2012

In CDC's July 2013 Mortality and Morbidity Report (MMWR), data from the 2012 National Immunization Survey (NIS) of teens showed HPV vaccination rates among 13- to 17-year-old girls remained unchanged from 2011. Numerous missed opportunities were found where a teen received at least one other recommended vaccination, but not the HPV vaccine. If HPV vaccine had been administered at the time of administration of other vaccines, vaccination coverage for ≥1 dose could be nearly 93% rather than 54%. Similar to 2011, only 1/3 of teenage girls have been fully vaccinated with all three doses.

agers.

CDC Director Tom Frieden, MD, MPH noted, "This report shows that HPV vaccine works well, and the report should be a wake-up call to our nation to protect the next generation by increasing HPV vaccination rates."

Even with low vaccination rates, the vaccine is having an impact on HPV infec-

tions. In the June 2013 issue of The Journal

women before and after the introduction of

National Health and Nutrition Examination

ger than expected 56% decrease in vaccine-

Survey (NHANES) data, they found a lar-

type HPV prevalence among female teen-

of Infectious Diseases, Markowitz et al. looked at HPV infections in girls and

the HPV vaccine in 2006. Using the

HPV vaccine may shield against throat cancer

A randomized clinical trial conducted in Costa Rica among 5,840 women ages 18-25 years old found that the bivalent vaccine provided 93% protection against HPV infections in the oral cavity compared

to those who were not vaccinated. Therefore, the HPV vaccine may protect against HPV-related throat cancers. About 70% of oropharyngeal cancers are now caused by HPV, up from 16% in the 1980s. (Herrero *et al.*, PLOS One)

>> Read the study: http://www.plosone.org/article/info% 3Adoi%2F10.1371%2Fjournal.pone.0068329

Dramatic decrease in new genital warts cases

The quadrivalent HPV vaccine is highly effective in reducing genital warts in Australia. In 2007, Australia implemented a nationally funded program to provide free quadrivalent HPV vaccinations to girls 12-13 years old. Five years into Australia's HPV vaccination program, Hammad and colleagues found a 59% decline of genital warts in young women, with the near disappearance in females under 21 (93% decline).

Genital wart cases among young heterosexual males also dropped by 39%, despite males not being part of the vaccination program. This is likely due to herd immunity, indirect protection of those who remain susceptible owing to a reduced prevalence of infections.



image via Carlos Reusser Monsalvez

>> Read the study here: www.bmj.com/content/346/bmj.f2032


CDC tips for talking with parents about HPV vaccine

A strong recommendation from the provider is the single best predictor of vaccination. Straightforward messages recommending the vaccine work with parents. CDC recommends that providers encourage HPV vaccination in the same way as other adolescent vaccines.

>> DOWLOAD THE TOOLKIT http://www.cdc.gov/vaccines/who/teens/for-hcptipsheet-hpv.pdf



The Advisory Committee on Immunization Practices: Human Papillomavirus Vaccine



HOW TO HELP

collect HPV vaccine history


To address low vaccine uptake, accreditation agencies have added HPV vaccination as a performance measure and health plans will be recognized for efforts to improve vaccination rates.

Documenting HPV vaccine history will be critical to these efforts and is an important part of providing good quality care. In 2012, only 12% of surveillance cases had HPV vaccine history in their medical record. We encourage women's health providers to take steps to improve vaccine documentation:

- 1) incorporate HPV vaccine history into intake, clinical assessment, and/or colposcopy forms,
- 2) institute chart prompts (electronic or manual) to remind staff to collect vaccination information or if vaccination status is missing,
- 3) use the CA Immunization Registry (CAIR) to record and look up vaccine history.

We may be able to help you with intake forms or tools for vaccine history documentation. For assistance, please contact us.





January 2014 **Cervical Cancer Awareness Month** Download free resources Fact sheets Booklets Guides

nttp://www.nccc-online.org

February 9-15, 2014

Preteen Vaccine Week



Preteen campaign kit available http://www.cdph.ca.gov/programs/immunize/ Pages/PreteenVaccineWeek.aspx

April 2014

STD Awareness Month



An estimated 19 million new STDs occur in the US each year. Provide patients with a Pocket Guide to STIs from

http://www.ashasexualhealth.org/april-is-stdawareness-month.html









We would love to hear from you

Contact Erin Whitney Erin.Whitney@cdph.ca.gov (510) 620-2379

Visit our site http://ceip.us/projects/ hpv-impact/